Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

27.80 -0.32 (-1.14%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield ↗

Today 10:20 EDT

The crowd is looking at the next couple of years. It should be looking five years into the future.

Via The Motley Fool

Topics Intellectual Property

3 Dirt Cheap Dividend Stocks Worth Buying in October ↗

Today 5:50 EDT

There are blazing deals for some of the top healthcare stocks -- companies with proven track records and dividend yields as high as 6%.

Via The Motley Fool

Topics Intellectual Property

My 3 Favorite Ultra-High-Yield Dividend Stocks to Buy for October ↗

Today 5:13 EDT

These stocks offer juicy yields and attractive risk-reward profiles.

Via The Motley Fool

Topics Artificial Intelligence Economy Energy

3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note ↗

October 03, 2026

With the 10-year Treasury yielding around 5.3%, Pfizer, Energy Transfer, and Plains All American offer stocks under $30 with dividend yields between 6% and 7%.

Via MarketBeat

Topics Bonds Retirement

Pfizer (NYSE:PFE) Nears Breakout as Technical Strength and Setup Quality Reach Top Marks ↗

September 24, 2026

Via Chartmill

Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy? ↗

October 03, 2026

Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers.

Via The Motley Fool

Topics Intellectual Property

Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP ↗

October 02, 2026

VanEck offers lower costs and double the dividend yield, while Invesco delivered stronger 1-year returns with more balanced holdings.

Via The Motley Fool

Topics ETFs

Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 02, 2026

Novo Nordisk boasts a 33% net margin and fortress balance sheet, while Pfizer trades cheaper but faces major patent cliffs through 2030.

Via The Motley Fool

Topics Intellectual Property

Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo

October 02, 2026

From Pfizer Inc

Via Business Wire

Pfizer Is Down 34% Over the Last 5 Years. Here's Why Its 6% Dividend Yield Might Finally Be Worth the Risk. ↗

October 02, 2026

Pfizer has been going through a period of transition.

Via The Motley Fool

Topics Earnings

Kevin Warsh's Inflation Stance Makes These Cheap Dividend Stocks Look a Lot More Attractive ↗

October 01, 2026

Inflation is running hot, and the Fed is raising interest rates, but consumers aren't likely to pull back on the products these companies sell.

Via The Motley Fool

Topics Economy

Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion ↗

October 01, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases,...

Via MarketBeat

Topics ETFs

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

October 01, 2026

From Pfizer Inc.

Via Business Wire

With the Market Flashing Warning Signs Not Seen Since the Dot-Com Bust, Is Pfizer's 6% Yield a Safe Haven or a Trap? ↗

September 29, 2026

While Pfizer's dividend looks like a trap, its strong balance sheet and low valuation make it safer.

Via The Motley Fool

Topics Intellectual Property World Trade

Here Are My Top 2 High-Yield Healthcare Stocks to Buy Now ↗

September 29, 2026

Pfizer and Bristol Myers Squibb pair big dividends with growing drug pipelines, a rare combination for income-focused pharma investors.

Via The Motley Fool

Topics Intellectual Property

Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO

September 28, 2026

From Pfizer Inc.

Via Business Wire

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗

September 28, 2026

Wall Street expects an even bigger rebound for this beaten-down biotech stock.

Via The Motley Fool

5 Dividend Stocks Yielding Over 5% With Fortress Financial Profiles to Buy Now ↗

September 27, 2026

These high-yielding stocks offer very durable dividends.

Via The Motley Fool

Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks. ↗

September 27, 2026

Pharmaceutical company share prices may suffer, but probably not by as much as some might fear.

Via The Motley Fool

Topics Bonds Economy

D-Wave Quantum vs. QuantumScape: Which Moonshot Tech Stock Is a Better Buy in 2026? ↗

September 26, 2026

Both companies are years from commercial scale and burning cash to get there. The difference is in how long each can keep going.

Via The Motley Fool

AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? ↗

September 25, 2026

AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.

Via The Motley Fool

Topics Intellectual Property

These S&P500 stocks are the most active in today's session ↗

September 24, 2026

Via Chartmill

Treasury Yields Hit a 19-Year High—These 2 Bond ETFs Offer Monthly Income ↗

September 24, 2026

As bond yields climb amid record U.S. debt, Vanguard's BSV and VCIT ETFs offer TTM yields of about 4% and 5%, respectively, with potential for rising monthly distributions.

Via MarketBeat

Topics Bonds ETFs

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 24, 2026

Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.

Via The Motley Fool

Topics Intellectual Property Regulatory Compliance

Viking's Obesity Edge May Be Staying Power, Not Weight Loss ↗

September 23, 2026

Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.

Via MarketBeat

Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts ↗

September 23, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development...

Via MarketBeat

Topics ETFs

Pfizer, Kraft, and UPS All Yield More Than 6%. Which of These Dividend Stocks Is the Safest Option Today? ↗

September 23, 2026

These are among the highest-yielding stocks on the S&P 500.

Via The Motley Fool

Topics Stocks

Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth? ↗

September 22, 2026

When investing in a dividend stock, it's important to consider not just the yield, but also the potential for dividend growth and overall risk.

Via The Motley Fool

Topics Economy

Pfizer Refocuses Growth Strategy as New Products Offset COVID Decline ↗

September 22, 2026

Pfizer (NYSE:PFE) has rebuilt its commercial model around newer and acquired products while reducing exposure to its COVID-19 franchise, according to Alexandre de Germay, the company’s chief...

Via MarketBeat

Topics Intellectual Property

AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September? ↗

September 22, 2026

These companies are committed to rewarding shareholders.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.